Literature DB >> 10227702

Antisense pharmacodynamics: critical issues in the transport and delivery of antisense oligonucleotides.

R L Juliano1, S Alahari, H Yoo, R Kole, M Cho.   

Abstract

This review critically examines current understanding of the kinetics and biodistribution of antisense oligonucleotides, both at the cellular level and at the level of the intact organism. The pharmacodynamic relationships between biodistribution and the ultimate biological effects of antisense agents are considered. The problems and advantages inherent in the use of delivery systems are discussed in the light of further enhancing in vivo pharmacological actions of oligonucleotides.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10227702     DOI： 10.1023/a:1011958726518

Source DB:  PubMed          Journal:  Pharm Res        ISSN： 0724-8741            Impact factor:   4.200


  104 in total

1.  Intracellular distribution of microinjected antisense oligonucleotides.

Authors:  J P Leonetti; N Mechti; G Degols; C Gagnor; B Lebleu
Journal:  Proc Natl Acad Sci U S A       Date:  1991-04-01       Impact factor: 11.205

2.  Integrin receptor-targeted transfer peptides for efficient delivery of antisense oligodeoxynucleotides.

Authors:  A S Bachmann; A Surovoy; G Jung; K Moelling
Journal:  J Mol Med (Berl)       Date:  1998-02       Impact factor: 4.599

Review 3.  In vivo studies with antisense oligonucleotides.

Authors:  S Akhtar; S Agrawal
Journal:  Trends Pharmacol Sci       Date:  1997-01       Impact factor: 14.819

4.  Up-regulation of luciferase gene expression with antisense oligonucleotides: implications and applications in functional assay development.

Authors:  S H Kang; M J Cho; R Kole
Journal:  Biochemistry       Date:  1998-05-05       Impact factor: 3.162

Review 5.  Pharmacokinetics of oligonucleotides.

Authors:  S Agrawal; R Zhang
Journal:  Ciba Found Symp       Date:  1997

6.  Inhibition of expression of the multidrug resistance-associated P-glycoprotein of by phosphorothioate and 5' cholesterol-conjugated phosphorothioate antisense oligonucleotides.

Authors:  S K Alahari; N M Dean; M H Fisher; R Delong; M Manoharan; K L Tivel; R L Juliano
Journal:  Mol Pharmacol       Date:  1996-10       Impact factor: 4.436

7.  Oligodeoxyribonucleotide uptake in primary human hematopoietic cells is enhanced by cationic lipids and depends on the hematopoietic cell subset.

Authors:  R Kronenwett; U Steidl; M Kirsch; G Sczakiel; R Haas
Journal:  Blood       Date:  1998-02-01       Impact factor: 22.113

8.  The activity of c-myb antisense oligonucleotide to prevent intimal hyperplasia is nonspecific.

Authors:  Y Castier; E Chemla; J Nierat; D Heudes; M A Vasseur; C Rajnoch; P Bruneval; A Carpentier; J N Fabiani
Journal:  J Cardiovasc Surg (Torino)       Date:  1998-02       Impact factor: 1.888

9.  Cellular and molecular barriers to gene transfer by a cationic lipid.

Authors:  J Zabner; A J Fasbender; T Moninger; K A Poellinger; M J Welsh
Journal:  J Biol Chem       Date:  1995-08-11       Impact factor: 5.157

10.  Pharmacokinetics and biodistribution of a nucleotide-based thrombin inhibitor in rats.

Authors:  L Reyderman; S Stavchansky
Journal:  Pharm Res       Date:  1998-06       Impact factor: 4.200
View more
  30 in total

1.  Enhanced delivery of antisense oligonucleotides with fluorophore-conjugated PAMAM dendrimers.

Authors:  H Yoo; R L Juliano
Journal:  Nucleic Acids Res       Date:  2000-11-01       Impact factor: 16.971

2.  Metabolic cleavage of cell-penetrating peptides in contact with epithelial models: human calcitonin (hCT)-derived peptides, Tat(47-57) and penetratin(43-58).

Authors:  Rachel Tréhin; Hanne M Nielsen; Heinz-Georg Jahnke; Ulrike Krauss; Annette G Beck-Sickinger; Hans P Merkle
Journal:  Biochem J       Date:  2004-09-15       Impact factor: 3.857

3.  Cellular internalization of human calcitonin derived peptides in MDCK monolayers: a comparative study with Tat(47-57) and penetratin(43-58).

Authors:  Rachel Tréhin; Ulrike Krauss; Roman Muff; Martina Meinecke; Annette G Beck-Sickinger; Hans P Merkle
Journal:  Pharm Res       Date:  2004-01       Impact factor: 4.200

4.  High-affinity aptamers to subtype 3a hepatitis C virus polymerase display genotypic specificity.

Authors:  Louisa A Jones; Leighton E Clancy; William D Rawlinson; Peter A White
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

Review 5.  Gene modulation for treating liver fibrosis.

Authors:  Kun Cheng; Ram I Mahato
Journal:  Crit Rev Ther Drug Carrier Syst       Date:  2007       Impact factor: 4.889

Review 6.  Bioconjugate-based molecular umbrellas.

Authors:  Vaclav Janout; Steven L Regen
Journal:  Bioconjug Chem       Date:  2009-02       Impact factor: 4.774

Review 7.  Magnetic nanoparticles in MR imaging and drug delivery.

Authors:  Conroy Sun; Jerry S H Lee; Miqin Zhang
Journal:  Adv Drug Deliv Rev       Date:  2008-04-10       Impact factor: 15.470

8.  A specific aptamer-cell penetrating peptides complex delivered siRNA efficiently and suppressed prostate tumor growth in vivo.

Authors:  Yanjun Diao; Jiayun Liu; Yueyun Ma; Mingquan Su; Hongyi Zhang; Xiaoke Hao
Journal:  Cancer Biol Ther       Date:  2016-03-08       Impact factor: 4.742

9.  Viewing membrane-bound molecular umbrellas by parallax analyses.

Authors:  Masaharu Kondo; Mohamed Mehiri; Steven L Regen
Journal:  J Am Chem Soc       Date:  2008-09-11       Impact factor: 15.419

10.  In ovo RNAi opens new possibilities for temporal and spatial control of gene silencing during development of the vertebrate nervous system.

Authors:  Thomas Baeriswyl; Esther T Stoeckli
Journal:  J RNAi Gene Silencing       Date:  2006-02-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.